Progress in the Management and Treatment of Diffuse Large B-Cell Lymphoma: Diagnosis, Risk Stratification and Novel Target Therapeutic Approaches
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".
Deadline for manuscript submissions: closed (30 September 2021) | Viewed by 414
Special Issue Editor
Special Issue Information
Dear Colleagues,
Since 2002, the addition of rituximab has improved the efficacy of the CHOP regimen in diffuse large B-cell lymphoma (DLBCL), with 55–60% of patients being cured, and it is still the standard of care today. However, 40–45% fail, and this has prompted many attempts to improve the efficacy of first-line treatment in DLBCL. Reasons for failure rely on the heterogeneity of DLBCL with different molecular varieties and different clinical aspects.
The risk stratification of DLBCL has already been established, but it should be refined, and some open issues remain, such as a risk of central nervous system progression.
Genetic subgroups, such as high-grade B-cell lymphomas with genetic anomalies of MYC, and/or other genes, such as BLC2, have been described, but they require a better description. Proper treatment for the most aggressive subgroups has not clearly established. Many attempts to improve the efficacy of first-line treatment in DLBCL have been studied in order to pass over the “wall” of R-CHOP, unfortunately with conflicting results. The treatment of relapsed/refractory patients has also improved, but it is still far from achieving satisfactory results. The introduction of novel targeted agents along with chemoimmunotherapy, or the introduction of novel antibodies and/or cellular immunotherapies, such as CART, promises to improve the outcomes of DLBCL.
With this Special Issue, I am proposing an extended review on these open issues and novel therapeutic approaches in DLBCL, with the aim to improve our knowledge in the management and treatment of DLBCL, focusing on the most aggressive subgroups.
Prof. Umberto Vitolo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- DLBCL
- rituximab-CHOP
- treatment
- prognosis
- targeted therapy
- immunotherapy
- cellular therapy
- high-grade B-cell lymphomas
- CART
- biological drugs
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
